Key advisors voted 9 to 2 that human trials of MDMA did not prove its efficacy, and 10 to 1 that risks outweigh benefits.
The vote highlighted challenges in assessing psychedelic drugs and the FDA's limited ability in evaluating psychiatric treatments.
[
Collection
]
[
|
...
]